BIOREGENX, INC. (BRGX) Form 10-Q — May 20, 2026
BioRegenx reported a net loss of $26,415 for the three months ended March 31, 2026, a significant improvement from the $266,854 loss in the prior year period, driven by a $100,435 write-off of unpayable accrued liabilities and reduced operating expenses. Despite the improved net loss, the company faces severe liquidity constraints with only $45,806 in cash, a stockholders' deficit of $4.5 million, and $522,500 in defaulted debt, including two EIDL loans and older private notes.
Key figures
- Eps
- 0
- Revenue
- 426175
- Total Debt
- 4870386
- Revenue Yoy
- -17
- Cash Position
- 45806
- Shares Outstanding
- 971575183
- Defaulted debt usd
- 522500
- Operating cash flow usd
- 26629
Price after filing
Close on the filing date to close N calendar days later (from $0.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.